

Aeglea BioTherapeutics, Inc.
 Form 3/A
 April 08, 2016

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
 Expires: January 31, 2015
 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

| | | | | |
|--|---|---|---|--|
| <p>1. Name and Address of Reporting Person *</p> <p>Â Novartis Bioventures Ltd</p> <p>(Last) (First) (Middle)</p> <p>131 FRONT STREET</p> <p>(Street)</p> <p>HAMILTON,Â D0Â HM12</p> <p>(City) (State) (Zip)</p> | <p>2. Date of Event Requiring Statement</p> <p>(Month/Day/Year)</p> <p>04/06/2016</p> | <p>3. Issuer Name and Ticker or Trading Symbol</p> <p>Aeglea BioTherapeutics, Inc. [AGLE]</p> | <p>4. Relationship of Reporting Person(s) to Issuer</p> <p>(Check all applicable)</p> <p><input type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner <input type="checkbox"/> Officer <input type="checkbox"/> Other (give title below) (specify below)</p> | <p>5. If Amendment, Date Original Filed(Month/Day/Year)</p> <p>04/06/2016</p> <p>6. Individual or Joint/Group Filing(Check Applicable Line)</p> <p><input type="checkbox"/> Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person</p> |
|--|---|---|---|--|

Table I - Non-Derivative Securities Beneficially Owned

| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
|------------------------------------|--|---|--|
|------------------------------------|--|---|--|

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
|---|---|--|--|--|--|
| | Date Exercisable Expiration Date | Title Amount or Number of Shares | | | |

| | | | | | | | |
|--------------------------|-------|-------|--------------|-----------|----------|-------|---|
| Series A Preferred Stock | Â (1) | Â (1) | Common Stock | 890,476 | \$ 0 (1) | D (2) | Â |
| Series B Preferred Stock | Â (1) | Â (1) | Common Stock | 1,120,448 | \$ 0 (1) | D (2) | Â |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|---|---------------|-----------|---------|-------|
| | Director | 10% Owner | Officer | Other |
| Novartis Bioventures Ltd 131 FRONT STREET HAMILTON,Â D0Â HM12 | Â | Â X | Â | Â |
| NOVARTIS AG LICHTSTRASSE 35 BASEL,Â V8Â CH 4056 | Â | Â X | Â | Â |

Signatures

| | |
|---|------------|
| /s/ Michael Jones, Deputy Chairman | 04/07/2016 |
| __Signature of Reporting Person | Date |
| /s/ Laurieann Chaikowsky, Authorized Signatory | 04/07/2016 |
| __Signature of Reporting Person | Date |
| /s/ Michael Jones, Authorized Signatory on behalf of Novartis AG | 04/07/2016 |
| __Signature of Reporting Person | Date |
| /s/ Laurieann Chaikowsky, Authorized Signatory on behalf of Novartis AG | 04/07/2016 |
| __Signature of Reporting Person | Date |

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Each share of Series A Preferred Stock and Series B Preferred Stock will be automatically converted into one (1) share of Common (1) Stock, for no additional consideration, immediately prior to the consummation of the Issuer's initial public offering, and has no expiration date.

(2) These securities are held directly by Novartis Bioventures Ltd. ("Novartis Bioventures"). Novartis Bioventures is a corporation organized under the laws of Bermuda and is an indirect wholly-owned subsidiary of Novartis AG. Novartis AG is a corporation organized under the laws of Switzerland and is the publicly owned parent of Novartis Bioventures Ltd.

Â

Remarks:

ThisÂ amendmentÂ isÂ beingÂ filedÂ solelyÂ toÂ addÂ theÂ powerÂ ofÂ attorney.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Edgar Filing: Aeglea BioTherapeutics, Inc. - Form 3/A

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.